title: Pharmacokinetics, metabolism and renal clearance of flumequine in veal calves.
abstract: The pharmacokinetics of flumequine was studied in 1-, 5- and 18-week-old veal calves. A two-compartment model was used to fit the plasma concentration-time curve of flumequine after the intravenous injection of 10 mg/kg of a 10% solution. The elimination half-life (t1/2 beta) of the drug ranged from 6 to 7 h. The Vd beta and ClB of 1-week-old calves (1.07 l/kg, 1.78 ml/min/kg) were significantly lower than those of 5-week-old (1.89 l/kg, 3.23 ml/min/kg) and 18-week-old calves (1.57 l/kg, 3.10 ml/min/kg). After the oral administration of 10 mg/kg of a 2% flumequine formulation mixed with milk replacer, the Cmax was highest in 1-week-old (9.27 micrograms/ml) and lowest in 18-week-old calves (4.47 micrograms/ml). The absorption was rapid (Tmax of approximately 3 h) and complete. When flumequine itself and a formulation containing 2% flumequine and 20 X 10(6) iu of colistin sulphate were mixed with milk replacer and administered at the same dose rate, absorption was incomplete and Cmax was lower. The main urinary metabolite of flumequine was the glucuronide conjugate (approximately 40% recovery within 48 h of intravenous injection) and the second most important metabolite was 7-hydroxy-flumequine (approximately 3% recovery within 12 h of intravenous injection). Only 3.2-6.5% was excreted in the urine unchanged. After oral administration a 'first-pass' effect was observed, with a significant increase in the excretion of conjugated drug. For 1-week-old calves it is recommended that the 2% formulation should be administered at a dose rate of 8 mg/kg every 24 h or 4 mg/kg every 12 h; for calves over 6 weeks old, the dose should be increased to 15 mg/kg every 24 h or 7.5 mg/kg every 12 h. The formulation containing colistin sulphate should be administered to 1-week-old calves at a flumequine dose of 12 mg/kg every 24 h or 6 mg/kg every 12 h.
authors.affiliation: Department of Large Animal Medicine and Nutrition, Veterinary Faculty, State University of Utrecht, The Netherlands.
authors.forename: D J
authors.initials: DJ
authors.lastname: Mevius
authors.forename: H J
authors.initials: HJ
authors.lastname: Breukink
authors.forename: P J
authors.initials: PJ
authors.lastname: Guelen
authors.forename: T
authors.initials: T
authors.lastname: Jansen
authors.forename: B
authors.initials: B
authors.lastname: De Grève
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D002417:Cattle / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D024841:Fluoroquinolones; D006207:Half-Life; D007275:Injections, Intravenous / Q000662:veterinary; D007668:Kidney / Q000378:metabolism; D016018:Least-Squares Analysis; D008297:Male; D008954:Models, Biological; D011807:Quinolizines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D012044:Regression Analysis
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D011807:Quinolizines; C012976:flumequine